Disease Groups Beg Congress For Antibiotics R&D Boost

Law360, New York (February 24, 2012, 7:31 PM EST) -- A coalition of 50 public health groups has sent letters to congressional leaders urging them to include incentives for new antibiotic research and development in the Prescription Drug User Fee Act and warned that a failure to act could set health care back decades, the groups said Thursday.

The groups, led by the Infectious Diseases Society of America, issued their warning in dire terms.

“If Congress does not enact strong solutions, we face a future that resembles the days before these miracle drugs were developed, one...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.